Compare Cassava Sciences Inc (FLNA) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Marqeta Inc — how do they compare? Cassava Sciences Inc trades at $1.09 (market cap $53.14M), while Marqeta Inc trades at $17.62 (market cap $1.83B). The key difference: Marqeta Inc is far larger — about 34.4× Cassava Sciences Inc's market cap, and Marqeta Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | MQ | |
|---|---|---|
Market Cap | $53.14M | $1.83B |
Sector | Health | Technology |
52-Week High | $4.64 | $27.32 |
52-Week Low | $1.09 | $15.04 |
Enterprise Value | -$33.43M | $1.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
MQ trades at $16.13, down 1.83% on the day, with a bullish technical signal from moving averages and oversold RSI. The company reported a Q1 2026 EPS beat of $0.08 versus -$0.0136 expected, though full-year 2025 revenue grew to $624.88M while net income was -$13.93M. A 4:1 reverse stock split took effect July 1, 2026, and expansion into 30 European markets via Banking Circle was announced May 26, 2026.
MQ's outlook is mixed: analyst consensus is a $19.00 price target with 32% buy ratings, but high valuation ratios (P/E 434.25) and thin net margins (0.33%) pose risks. Positive cash flow trends and credit market expansion offer growth potential, yet shareholder litigation and volatile earnings history require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
